Home > Oncology > ELCC 2022 > Advanced Non-Small Cell Lung Cancer > Sintilimab plus chemotherapy improves OS in treatment-naïve, stage III–IV non-squamous NSCLC

Sintilimab plus chemotherapy improves OS in treatment-naïve, stage III–IV non-squamous NSCLC

Presented By
Dr Yunpeng Yang, Sun Yat-sen University Cancer Center, China
Conference
ELCC 2022
Trial
Phase 3, ORIENT-11
Doi
https://doi.org/10.55788/4c88e56b
The final results of the phase 3 ORIENT-11 trial showed an improved overall survival (OS) in patients with treatment-naïve, stage III–IV non-squamous non-small cell lung cancer (NSCLC) treated with sintilimab plus chemotherapy versus placebo plus chemotherapy. Antibodies directed at PD-1/PD-L1 are effective therapies for previously untreated patients with metastatic non-squamous NSCLC who do not harbour driver gene mutations. Sintilimab is a selective anti-PD-1 antibody. Preclinical data indicated that sintilimab has a different binding site and therefore potentially greater affinity against PD-1 compared with pembrolizumab or nivolumab [1]. In the phase 3 ORIENT-11 trial (NCT03607539), first-line treatment with sintilimab plus pemetrexed-platinum chemotherapy significantly improved progression-free survival (PFS) compared with placebo plus chemotherapy in patient...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on